$94.9 B

AZN Mkt cap, 15-Oct-2018

£22.5 B

AstraZeneca Revenue FY, 2017
AstraZeneca Gross profit (FY, 2017)18.1 B
AstraZeneca Gross profit margin (FY, 2017), %80.8%
AstraZeneca Net income (FY, 2017)2.9 B
AstraZeneca EBITDA (FY, 2017)6.7 B
AstraZeneca EBIT (FY, 2017)3.7 B
AstraZeneca Cash, 31-Dec-20173.3 B
AstraZeneca EV93.9 B

AstraZeneca Revenue

AstraZeneca revenue was £22.46 b in FY, 2017

Embed Graph

AstraZeneca Revenue Breakdown

Embed Graph

AstraZeneca revenue breakdown by business segment: 22.3% from Respiratory, Inflammation and Autoimmunity, 23.8% from Infection, Neuroscience and Gastrointestinal:, 15.9% from Oncology and 38.1% from Cardiovascular and Metabolic Diseases

AstraZeneca Income Statement

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Revenue

5.4b5.2b5.5b11.4b12.1b11.4b11.1b10.5b11.5b14.0b13.5b14.8b19.8b16.9b19.6b19.1b23.0b22.5b

Revenue growth, %

1%(9%)(10%)

Cost of goods sold

2.2b2.0b2.2b3.7b3.7b3.1b2.8b2.5b2.8b3.1b2.7b3.2b4.1b3.5b4.3b3.6b4.1b4.3b

Gross profit

3.1b3.2b3.4b7.6b8.4b8.3b8.3b8.0b8.7b10.8b10.8b11.6b15.7b13.4b15.3b15.5b18.9b18.1b

Gross profit Margin, %

58%62%61%67%70%73%75%76%76%78%80%78%79%80%78%81%82%81%

Operating expense total

2.2b2.2b2.4b5.9b5.8b5.6b5.8b5.7b6.2b7.0b6.6b7.6b10.0b11.0b13.7b12.4b14.0b14.5b

Depreciation and amortization

4.6b3.3b2.9b

EBITDA

4.9b4.9b7.0b3.0b4.0b6.7b

EBITDA margin, %

36%33%35%18%20%30%

EBIT

942.0m1.0b982.0m1.7b2.7b2.7b2.5b2.3b2.6b3.8b4.2b4.1b5.7b2.4b1.6b3.2b4.9b3.7b

EBIT margin, %

18%19%18%15%22%24%22%22%22%27%31%27%29%14%8%17%21%16%

Pre tax profit

975.0m1.1b1.0b1.2b2.6b2.8b2.5b2.3b2.7b3.9b4.4b4.0b5.4b2.1b921.4m2.4b3.6b2.2b

Income tax expense

(320.0m)(345.0m)(330.0m)(502.0m)(869.0m)(762.0m)(735.0m)(639.0m)(671.0m)(1.1b)(1.3b)(1.2b)(1.6b)(457.7m)(8.1m)(188.2m)(146.0m)641.0m

Net Income

655.0m736.0m715.0m704.0m1.7b2.1b1.8b1.7b2.1b2.8b3.1b2.8b3.8b1.7b913.3m2.2b3.4b2.9b

AstraZeneca Balance Sheet

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Cash

259.0m303.0m206.0m265.0m683.0m489.0m453.0m409.0m565.0m2.9b3.6b2.9b2.7b6.1b4.7b4.8b5.0b3.3b

Accounts Receivable

935.0m969.0m1.1b1.8b1.8b1.7b1.7b1.8b1.9b2.2b2.2b2.7b3.5b3.6b3.5b3.6b2.6b2.8b

Inventories

681.0m728.0m798.0m1.3b1.4b1.7b1.6b1.7b1.6b1.3b1.2b1.1b1.0b1.3b1.4b1.7b2.3b3.0b

Current Assets

3.0b2.9b2.7b6.1b7.0b6.8b7.6b7.2b7.7b8.0b8.7b8.6b10.0b13.2b12.2b12.3b13.0b12.9b

PP&E

1.9b2.1b2.4b3.8b3.3b3.8b4.1b4.3b4.5b4.9b3.8b4.2b4.4b3.8b4.4b7.6b10.3b7.6b

Goodwill

17.1b24.1b25.5b30.4b

Total Assets

5.0b5.0b5.5b12.2b12.3b12.5b13.5b13.2b13.7b14.5b15.3b24.1b29.4b36.8b43.3b46.5b62.5b63.4b

Accounts Payable

479.0m529.0m588.0m997.0m2.0b1.7b2.0b1.7b1.7b1.8b1.8b1.8b2.4b1.6b2.6b2.7b10.5b11.6b

Current Liabilities

1.9b1.9b2.1b4.3b4.6b4.5b5.1b4.3b4.2b4.0b4.8b7.6b8.4b10.6b12.8b11.5b15.3b16.4b

Non-Current Liabilities

1.1b987.0m893.0m1.5b1.3b1.2b1.4b1.5b1.8b2.6b2.6b9.0b11.0b10.9b16.0b20.7b32.4b32.0b

Total Debt

103.0m76.0m135.0m126.0m85.0m75.0m52.0m69.0m2.1b102.3m1.2b144.9m2.3b2.2b

Total Liabilities

3.0b2.8b3.0b5.9b6.0b5.7b6.5b5.8b6.0b6.6b7.5b16.6b19.4b21.5b28.8b32.2b47.7b48.4b

Additional Paid-in Capital

237.0m237.0m238.0m274.0m296.0m302.0m268.0m236.0m220.0m230.0m196.0m183.0m227.1m207.1m233.7m244.7m316.0m317.0m

Retained Earnings

311.0m365.0m315.0m(61.0m)(245.0m)1.2b1.0b942.0m1.2b1.8b2.0b1.5b2.1b1.7b(1.7b)(511.2m)3.3b2.7b

Total Equity

2.0b2.2b2.5b6.4b6.4b6.8b7.0b7.4b7.7b7.9b7.8b7.4b10.0b15.3b14.5b14.3b14.9b15.0b

Debt to Equity Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0.3 x0 x0.1 x0 x0.2 x0.2 x

Debt to Assets Ratio

0 x0 x0 x0 x0 x0 x0 x0 x0.1 x0 x0 x0 x0 x0 x

Financial Leverage

2.5 x2.3 x2.2 x1.9 x1.9 x1.8 x1.9 x1.8 x1.8 x1.8 x2 x3.2 x2.9 x2.4 x3 x3.2 x4.2 x4.2 x

AstraZeneca Cash Flow

Annual

GBPFY, 1996FY, 1997FY, 1998FY, 1999FY, 2000FY, 2001FY, 2002FY, 2003FY, 2004FY, 2005FY, 2006FY, 2007FY, 2008FY, 2013FY, 2014FY, 2015FY, 2016FY, 2017

Net Income

655.0m736.0m715.0m704.0m1.7b2.1b1.8b1.7b2.1b2.8b3.1b2.8b3.8b1.7b913.3m2.2b3.4b2.9b

Cash From Operating Activities

1.1b1.2b1.2b1.9b2.8b2.6b3.5b2.4b3.2b3.9b3.9b3.8b5.5b4.9b5.2b4.0b4.1b3.6b

Dividends Paid

332.0m365.0m399.0m764.0m1.9b850.0m753.0m754.0m833.0m976.0m1.1b1.3b1.7b2.6b2.7b

Cash From Financing Activities

(39.0m)(32.0m)(96.0m)(112.0m)(267.0m)(665.0m)(794.0m)(811.0m)(740.0m)(2.7b)(2.7b)3.0b(4.0b)(2.0b)(2.0b)3.4b(1.3b)(2.9b)

Net Change in Cash

101.0m73.0m112.0m172.0m428.0m275.0m14.0m2.0m165.0m576.0m1.1b665.0m(951.2m)962.7m(2.0b)(28.7m)(1.1b)(1.7b)

Income Taxes Paid

(457.7m)(8.1m)(179.7m)(113.1m)

AstraZeneca Ratios

GBPY, 2017

EV/EBITDA

14 x

EV/EBIT

25.5 x

EV/CFO

26.2 x

Revenue/Employee

367.7k

Debt/Equity

0.2 x

Financial Leverage

4.2 x
Report incorrect company information

AstraZeneca Operating Metrics

FY, 2013FY, 2014FY, 2015FY, 2016

Healthcare Workers

2.60 k3 k

Countries

100 100 100 100

Drugs Approved by FDA

1

Health Facilities Activated

250 403

NME in Late-stage Development

7 13 15 12

Phase I Trials Products

33 24 44 41

Phase II Trials Products

27 11 33 36

Phase III Trials Products

19 11 35 27

Projects in R&D Pipeline

99 133 146 132

Young Health Programme Members

1.40 m1.60 m
Report incorrect company information